Their discoveries are
transforming
the way that we
understand disease.
This not only
positions Canada
as a leader
in biomedical research,
but is leading the
way towards how
patients will be cared
for in the future.
L to R: Brent Belzberg, Foundation Management Board Chair; The Honourable Kathleen Wynne,
Premier of Ontario; Larry and Judy Tanenbaum; Jay Hennick, Hospital Board Chair and
Joseph Mapa, President and CEO of Mount Sinai Hospital.
—
L a r r y Ta n e n b a u m
there is so much more to learn and to improve. This helps us meet our goals
of better health through research."
A major goal for the research institute over the next few years is to
achieve even stronger collaborations between research and clinical practice
at Mount Sinai — a goal this gift will help enable. These partnerships are
driven by discoveries at the Lunenfeld-Tanenbaum Research Institute which,
when translated to the patient's bedside, can impact the treatment of our
most debilitating diseases. "My vision is that this integration between the
research bench and patient care will become the prototype for the future of
health care," says Dr. Woodgett.
This investment will support the research of internationally recognized
investigators — like Drs. Helen McNeill, Ravi Retnakaran and Mei Zhen
to name a few — who are working towards the prevention, detection and
treatment of health conditions aligned with Mount Sinai's flagship clinical
programs including cancer, diabetes, rheumatoid arthritis, maternal and
infant health, neurodegenerative diseases and mental health disorders.
We thank Larry and Judy for their extraordinary generosity and vision.
Read on to see how
donor support fuels
everything we do
at Mount Sinai.
To make your own investment in research, please visit
us at supportsinai.ca or call 416-586-8203.
t h e b e st m e d i c i n e m att e r s 3
